Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
13 authors.
Ivan GazievInstitute for Personalized Oncology, Biomedical Science & Technology Park, FSAEI HE I.M. Sechenov First Moscow State Medical University of MOH of Russia (Sechenovskiy University), 119991 Moscow, Russia.ORCID 0009-0006-8751-0434
Anna KhristichenkoDepartment of Genetics and Life Sciences, Sirius University of Science and Technology, 354340 Sirius Federal Territory, Russia.ORCID 0000-0003-1375-4808
Daniil LuppovInstitute for Personalized Oncology, Biomedical Science & Technology Park, FSAEI HE I.M. Sechenov First Moscow State Medical University of MOH of Russia (Sechenovskiy University), 119991 Moscow, Russia.ORCID 0000-0002-4993-8636
Maria SuntsovaInstitute for Personalized Oncology, Biomedical Science & Technology Park, FSAEI HE I.M. Sechenov First Moscow State Medical University of MOH of Russia (Sechenovskiy University), 119991 Moscow, Russia.
Ekaterina BondarenkoNational Medical Research Center for Endocrinology, 117292 Moscow, Russia.ORCID 0000-0003-2122-2297
Maria ReinbergNational Medical Research Center for Endocrinology, 117292 Moscow, Russia.
Alina MatrosovaInstitute for Personalized Oncology, Biomedical Science & Technology Park, FSAEI HE I.M. Sechenov First Moscow State Medical University of MOH of Russia (Sechenovskiy University), 119991 Moscow, Russia.
Nadezhda KhilalInstitute for Personalized Oncology, Biomedical Science & Technology Park, FSAEI HE I.M. Sechenov First Moscow State Medical University of MOH of Russia (Sechenovskiy University), 119991 Moscow, Russia.ORCID 0000-0001-8367-6118
Maksim SorokinInstitute for Personalized Oncology, Biomedical Science & Technology Park, FSAEI HE I.M. Sechenov First Moscow State Medical University of MOH of Russia (Sechenovskiy University), 119991 Moscow, Russia.ORCID 0000-0001-7685-3446
Marina SekachevaInstitute for Personalized Oncology, Biomedical Science & Technology Park, FSAEI HE I.M. Sechenov First Moscow State Medical University of MOH of Russia (Sechenovskiy University), 119991 Moscow, Russia.ORCID 0000-0003-0015-7094
Elena PoddubskayaInstitute for Personalized Oncology, Biomedical Science & Technology Park, FSAEI HE I.M. Sechenov First Moscow State Medical University of MOH of Russia (Sechenovskiy University), 119991 Moscow, Russia.ORCID 0000-0001-6476-6337
Anton BuzdinInstitute for Personalized Oncology, Biomedical Science & Technology Park, FSAEI HE I.M. Sechenov First Moscow State Medical University of MOH of Russia (Sechenovskiy University), 119991 Moscow, Russia.
Galina ZakharovaInstitute for Personalized Oncology, Biomedical Science & Technology Park, FSAEI HE I.M. Sechenov First Moscow State Medical University of MOH of Russia (Sechenovskiy University), 119991 Moscow, Russia.ORCID 0000-0002-2548-8511
Funding
Russian Science Foundation 25-75-20022
6 · The paper itself
Abstract
Accurate detection of oncogenic gene fusions is becoming increasingly important given the availability of highly effective targeted therapies. However, their identification in clinical practice remains challenging due to the rarity of individual events, diversity of partner genes, and variability of breakpoint locations. Conventional approaches such as immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) lack multiplexing capacity and demonstrate variable sensitivity and specificity, while direct identification of fusion transcripts in whole-transcriptome sequencing (RNA-seq) profiles provides broader applicability but limited sensitivity, as fusion junctions are frequently supported by a minimal number of reads or even no reads at all. In this study, a novel approach was employed to accurately detect clinically actionable
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.